-
Mashup Score: 0Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A Phase II LCMC3 trial showed that patients with resectable Stage IB-IIIB non-small cell #lungcancer receiving adjuvant atezolizumab following neoadjuvant atezolizumab and resection had improved disease-free survival. #ELCC23 https://t.co/vD0EhxrLkn https://t.co/FYnxtUdbAN
-
-
Mashup Score: 3Radiation Oncologist Makes Case for Radiotherapy for Local Treatment of Select Patients - ILCN.org (ILCN/WCLC) - 11 month(s) ago
Can radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During #ELCC23, Dr. Sara Ramella examined if radiotherapy can replace surgery in stage III NSCLC in the era of immunotherapy. Read a recap in #ILCN: https://t.co/h0WY3ToMAJ #LCSM
-
-
Mashup Score: 2ELCC Session Offers Surgical Perspective in Context of Neoadjuvant Immunotherapy - ILCN.org (ILCN/WCLC) - 11 month(s) ago
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #ELCC23, @brunellialex addressed common concerns related to neoadjuvant therapies. Read a recap in #ILCN: https://t.co/EWVPAuo6hf #LCSM
-
-
Mashup Score: 0Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC - 11 month(s) ago
The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer. #ELCC23 #lcsm https://t.co/7G1wI8YdK9
-
-
Mashup Score: 1Early Detection Researcher Shares Epidemiologic Evidence on Air Pollution, Lung Cancer - ILCN.org (ILCN/WCLC) - 11 month(s) ago
Dr. Christine Berg says both smoking and air pollution are important in causing lung cancer. And both need to be eliminated to help prevent it and save lives.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During #ELCC23, Dr. Christine Berg shared epidemiological insights about air pollution and #lungcancer. Read a recap in #ILCN: https://t.co/O76ybp2PP4 #LCSM
-
-
Mashup Score: 1Amivantamab Demonstrates Consistent Efficacy in CHRYSALIS Follow-up - ILCN.org (ILCN/WCLC) - 11 month(s) ago
Spain’s Dr. Pilar Garrido reviews long-term efficacy, safety, and predictors-of-response data for post-platinum advanced NSCLC patients with EGFR exon 20 insertion mutations.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #ELCC23, @Piuchagarrido presented long-term data on amivantamab from a phase 1 CHRYSALIS trial cohort. Read a recap in #ILCN: https://t.co/0qjkdMEWjI #LCSM
-
-
Mashup Score: 2Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions - The ASCO Post - 12 month(s) ago
Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging long-term benefits and consistent efficacy in patients with advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions, according to data presented by Pilar Garrido, MD, PhD, Associate Professor of Oncology at the Universidad de Alcalá and Head of the Medical Oncology Department at the…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions https://t.co/iv7CriBjkh #LCSM #lungcancer #oncology #immunotherapy #ELCC23
-
-
Mashup Score: 0Front-Line vs Sequential Use of Osimertinib in EGFR-Mutant NSCLC: Potential Impact of Liquid Biopsies - The ASCO Post - 12 month(s) ago
Using liquid biopsies to detect circulating tumor DNA (ctDNA) may soon transform treatment strategies for patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023 by lead study author Jordi Remon, MD, PhD, of Gustave Roussy, France.1 Authors of the study underscored the potential impact of using liquid…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Front-Line vs Sequential Use of Osimertinib in EGFR-Mutant NSCLC: Potential Impact of Liquid Biopsies https://t.co/Nv0zbZpLyg #LCSM #lungcancer #ELCC23 #oncology
-
-
Mashup Score: 5CheckMate 816: 3-Year Update Shows Improved Event-Free Survival With Neoadjuvant Nivolumab and Chemotherapy for Resectable NSCLC - The ASCO Post - 12 month(s) ago
The combination of neoadjuvant nivolumab plus chemotherapy continues to demonstrate potential as a standard treatment for patients with resectable non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023.1 The 3-year update from the phase III CheckMate 816 study showed statistically significant and clinically meaningful improvements in…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CheckMate 816: 3-Year Update Shows Improved Event-Free Survival With Neoadjuvant Nivolumab and Chemotherapy for Resectable NSCLC https://t.co/i1iGY9DRR9 #ELCC23 #LCSM #lungcancer #oncology #immunotherapy
-
A Phase II LCMC3 trial showed that patients with resectable Stage IB-IIIB non-small cell #lungcancer receiving adjuvant atezolizumab following neoadjuvant atezolizumab and resection had improved disease-free survival. #ELCC23 https://t.co/vD0EhxrLkn https://t.co/BHudZzvTR4